SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) today announced an update for the previously reported Roche-sponsored international Phase III clinical study AVAiL of Avastin([R]) bevacizumab in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer NSCLC. The update confirmed the clinically and statistically...
SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) today announced that the U.S. Food and Drug Administration FDA granted accelerated approval for Avastin([R]) bevacizumab, in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer. The approval is based on...
Research suggests Avastin's market share will more than double in both first- and second-line therapy use in patients with HER2 negative metastatic breast cancer
SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) announced today that the company resubmitted a supplemental Biologics License Application sBLA to the U.S. Food and Drug Administration FDA for Avastin([R]) bevacizumab, in combination with paclitaxel chemotherapy, for patients who have not received chemotherapy for their locally recurrent or metastatic breast...
GENENTECH HAS established the price for the off-label use of its colorectal cancer drug Avastin at $100,000. What has critics up in arms is not only the cost but also the message it sends.
The landmark approval of the drug Avastin, which validates researchers' decades-long effort to battle cancer by cutting off the blood supply that feeds it, is expected to give biotech firms working on new cancer drugs a big boost. Avastin, made by The landmark...
THE GLOOMY results of Phase III trials for Genentech Inc.'s cancer drug Avastin (bevacizumab, rhuMAb-VEGF) sent shock waves across the market for a new class of anticancer drugs last week. While analysts maintain earnings per share forecasts, targe THE GLOOMY results of Phase III...
GENENTECH INC. reported positive Phase III trial data for its anti-angiogenic drug Avastin bevacizumab in colorectal cancer, positioning the company to file a biologics license application BLA later this year. GENENTECH INC. reported positive Phase III trial data for its anti-angiogenic...
SANTA MONICA, Calif., April 11 /U.S. Newswire/ -- Genentech posted a 48 percent profit increase today for the first quarter of 2006 following a recent announcement that the company would double the price of its cancer drug Avastin, to over $100,000 per yeSANTA MONICA, Calif., April 11 /U.S. Newswire/ --...
Stopping Sign-Ups: A safety review board halted enrollment in a clinical trial involving Avastin, a colon cancer drug manufactured by South San Francisco-based Genentech in its San Diego plant. Genentech announced it would stop enrolling people in Stopping Sign-Ups: A safety review board...
GENENTECH INC. is seeking early approval for its newest oncology product Avastin bevacizumab with its filing of a completed biologics license application with the Food and Drug Administration FDA last week. The company is requesting priority re GENENTECH INC. is seeking early approval for...
What keeps a biotechnology company from continuing a human clinical trial even if it finds potentially harmful data? After all, halting a clinical trial, even temporarily, can drop a firm's share price, as in the case of Anadys Pharmaceuticals Inc What keeps a...
The saga of Avastin and Lucentis -- two Genentech drugs used to treat a blinding condition called age-related macular degeneration, even though one is about 50 times cheaper than the other -- is one of those stories that just gets better the longer it goes on. A...
Negative public opinion just keeps piling on to Genentech regarding its pricing policy on Lucentis and Avastin. This weekend saw a big Associated Press story describe how the company is refusing to ask the FDA to approve Avastin for use in treating "wet age-related macular degeneration," an eye condition that...
A handful of scientists are skeptical that Genentech's C-08 trial of its Avastin anti-cancer drug will show any benefit in preventing the recurrence of colorectal cancer following surgery, reports PharmaWire via the Financial Times. Avastin is one of Genentech's most valuable products, and currently rakes in sales...
Earlier this week, the WSJ noted that oncologists are getting squeezed on the cost of expensive cancer drugs. Although the story features the usual anecdotes of doctors whose practices are in debt or who are shunting patients off to hospitals for treatment in order to save money, it's still hard...
WASHINGTON -- What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing. ...
Genentech Inc. rejected Roche Holding AG's $43.7 billion takeover bid, as Genentech shares closed 11 percent higher than the offer. The biotechnology company said it was open to further talks. Roche, of Basel, Switzerland, said July 21 it would pay $89 a share for the 44...
HOUSTON, July 1 /PRNewswire/ -- Agennix Incorporated today announced the publication of final results from a Phase 2 monotherapy trial with talactoferrin alfa in patients who had failed previous treatment for advanced or metastatic renal cell carcinoma RCC. Results from the study, which were reported...
SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based biomodulator of 5-FU (5 fluorouracil), for the treatment of first-line metastatic colorectal cancer. The primary...
Innovative USB Sleep'n Charge. Stylish Fusion™ finish. Ultra-portable. It's clear why the Satellite® U405 is a smart choice for you and your small business. Only from the laptop expert, Toshiba.
